|
Oct 9
|
FibroGen Inc (FGEN) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Shifts
|
|
Jul 29
|
FibroGen, Inc. (NASDAQ:FGEN) is a favorite amongst institutional investors who own 54%
|
|
Apr 6
|
Aldeyra (ALDX) Stock Rallies 43% in One Week: Here's Why
|
|
Apr 3
|
Evaxion (EVAX) Up on Upbeat Preclinical S. Aureus Vaccine Data
|
|
Apr 2
|
FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer
|
|
Mar 28
|
Apogee (APGE) Stock Rallies 95.6% in a Month: Here's Why
|
|
Mar 27
|
Stoke Therapeutics (STOK) Up on Upbeat Dravet Syndrome Study Data
|
|
Mar 26
|
FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference
|
|
Dec 9
|
FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower Risk Transfusion-Dependent Myelodysplastic Syndromes at American Society of Hematology Annual Meeting
|
|
Nov 7
|
FibroGen, Inc. (NASDAQ:FGEN) Q3 2023 Earnings Call Transcript
|
|
Nov 7
|
Q3 2023 FibroGen Inc Earnings Call
|
|
Nov 6
|
FibroGen Inc (FGEN) Reports 155% YoY Increase in Q3 2023 Net Revenue
|
|
Nov 6
|
FibroGen (FGEN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
|
|
Nov 6
|
FibroGen Reports Third Quarter 2023 Financial Results
|
|
Oct 23
|
FibroGen to Report Third Quarter 2023 Financial Results
|
|
Jul 14
|
FibroGen (FGEN) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
|